BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11741126)

  • 1. Oral treatment of erectile dysfunction with apomorphine SL.
    Altwein JE; Keuler FU
    Urol Int; 2001; 67(4):257-63. PubMed ID: 11741126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
    Mulhall JP; Bukofzer S; Edmonds AL; George M;
    Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
    Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
    BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
    Dula E; Bukofzer S; Perdok R; George M;
    Eur Urol; 2001 May; 39(5):558-3; discussion 564. PubMed ID: 11464037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine: an update of clinical trial results.
    Heaton JP
    Int J Impot Res; 2000 Oct; 12 Suppl 4():S67-73. PubMed ID: 11035390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
    Dula E; Keating W; Siami PF; Edmonds A; O'neil J; Buttler S
    Urology; 2000 Jul; 56(1):130-5. PubMed ID: 10869641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men.
    Gontero P; D'Antonio R; Pretti G; Fontana F; Panella M; Kocjancic E; Allochis G; Frea B
    Int J Impot Res; 2005; 17(1):80-5. PubMed ID: 15510184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual apomorphine for the treatment of erectile dysfunction.
    Mulhall JP
    Expert Opin Investig Drugs; 2002 Feb; 11(2):295-302. PubMed ID: 11829718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.
    Morales A
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S29-34. PubMed ID: 11477489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction.
    Hagemann JH; Berding G; Bergh S; Sleep DJ; Knapp WH; Jonas U; Stief CG
    Eur Urol; 2003 Apr; 43(4):412-20. PubMed ID: 12667723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study.
    Caruso S; Intelisano G; Farina M; DiMari L; Agnello C; Giammusso B
    Urology; 2003 Nov; 62(5):922-7. PubMed ID: 14624921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings.
    Riley A; Main M; Morgan F
    J Sex Med; 2010 Apr; 7(4 Pt 1):1508-17. PubMed ID: 19845547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin.
    Prescrire Int; 2002 Jun; 11(59):76-9. PubMed ID: 12068841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety of apomorphine SL (Ixense (TM) ).
    Montorsi F
    Int J Impot Res; 2003 Apr; 15 Suppl 2():S7-9. PubMed ID: 12825097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of apomorphine SL (Uprima).
    Bukofzer S; Livesey N
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S40-4. PubMed ID: 11477491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction.
    Heaton JP
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S35-9. PubMed ID: 11477490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating dose regimens of apomorphine, an open-label study.
    Kongkanand A; Opanuraks J; Tantiwongse K; Choeypunt N; Tantiwong A; Amornvejsukit T
    Int J Impot Res; 2003 Apr; 15 Suppl 2():S10-2. PubMed ID: 12825098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury.
    Strebel RT; Reitz A; Tenti G; Curt A; Hauri D; Schurch B
    BJU Int; 2004 Jan; 93(1):100-4. PubMed ID: 14678378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction.
    Wagner G
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S1-2. PubMed ID: 11477485
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
    Pavone C; Curto F; Anello G; Serretta V; Almasio PL; Pavone-Macaluso M
    J Urol; 2004 Dec; 172(6 Pt 1):2347-9. PubMed ID: 15538264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.